While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Google released the December 2025 core update today, the company announced. This is the third core update of 2025 and the fourth major Google algorithm update overall. Earlier this year, Google rolled ...

Many problems connected with processing of redundant measurement data have a nonlinear character. To solve these problems with in the stochastic approach, the developers apply different suboptimal ...

Landlords could no longer rely on rent-pricing software to quietly track each other's moves and push rents higher using confidential data, under a settlement between RealPage Inc. and federal ...

SAN FRANCISCO, Oct 22 (Reuters) - Google said it has developed a computer algorithm that points the way to practical applications for quantum computing and will be able to generate unique data for use ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...